Research News

Phase II Trial Points to Possible Benefits of IP Chemotherapy after Neoadjuvant Therapy and Surgery

(December 4, 2017) The results of a phase II trial, which focused on stages IIB to IVA epithelial ovarian cancer, were recently published in the Annals of Oncology…

Read on

OCRFA Funded Research Identifies Mechanism Underlying Ovarian Cancer Development

(November 22, 2017) A recent paper published in the Journal of Clinical Investigation reports that a subset of ovarian cancers reduce the expression of a critical gene involved in recycling the cells’ proteins, known as ubiquitin B (UBB)…

Read on

New Research Indicates that High Grade Serous Ovarian Carcinomas Originate in the Fallopian Tubes

(October 30, 2017) Until recently, it was thought that high-grade serous ovarian carcinomas (HGSOCs) arose from the ovarian surface epithelium, but recent data from two studies published in Nature Communications suggest that all high grade serous…

Read on

White Blood Cells Found in High Grade Ovarian Cancer May Point to Survival Outcomes

(October 20, 2017) An international, large scale study may have found a link between high-grade ovarian cancer and a type of white blood cell known as a tumor-infiltrating lymphocyte…

Read on

OCRFA Funded Study Discovers 3 Key Genes in Prevention and Treatment of BRCA1 and BRCA2 Tumors

(October 19, 2017) BRCA1 and BRCA2 are among the most frequently mutated genes in ovarian cancer…

Read on

Adjuvant Chemotherapy Does Not Lead to Better Survival In Certain Ovarian Cancers

(October 13, 2017) The National Comprehensive Cancer Network currently recommends that early stage Ovarian Clear Cell Cancers be treated with adjuvant chemotherapy, or therapy given after the primary treatment as a way to lower the risk of…

Read on

Studies Show that Current Chemotherapy Dosage is Still Best Option for Epithelial Ovarian Cancer

(September 15, 2017) Two studies just confirmed that, depending on one’s genetic background, the standard treatment for epithelial ovarian cancer is most likely the best option…

Read on

The Link Between Chemotherapy Resistance and a Tumor’s BRCA1/2 Mutations

(September 5, 2017) Researchers at the University of Pennsylvania recently uncovered a link between one’s resistance to common types of chemotherapy and one’s tumor BRCA1/2 mutation status…

Read on

Genetic Testing Rates Found to be Low in Women With A History of Breast or Ovarian Cancer

(August 22, 2017) The Journal of Clinical Oncology recently published a study about the unmet need of genetic testing in women with breast and ovarian cancer…

Read on

FDA Approves New Indication and Formulation for Olaparib

(August 21, 2017) The US Food and Drug Administration (FDA) has granted full approval to olaparib tablets (Lynparza, AstraZeneca) for use as maintenance therapy for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal…

Read on

Age When Giving Birth and Oral Contraceptives Influence One’s Risk of Ovarian Cancer

(August 9, 2017) The International Journal of Cancer recently published an article on preliminary findings for two factors that influence one’s risk of ovarian cancer, namely the age at which a woman gives birth and the age at which she starts…

Read on

Updated Patient Resources for Ovarian Cancer from the National Comprehensive Cancer Network

(July 31, 2017) The National Comprehensive Cancer Network (NCCN), has updated and published guidelines for patients with ovarian cancer. There are two parts to the resource guide: The Guidelines for Patients and Quick Guides…

Read on